What to do at step 3 of the asthma guidelines - Increase the dose of inhaled corticosteroids or add a long-acting β-agonist drug?

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 1, 2003, Pages 10-11

  Masoli, Matthew ^a   Holt, Shaun ^b   Beasley, Richard ^a,c  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b P3 Research   (New Zealand)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asthma; Guidelines; Inhaled corticosteroids; Long acting beta antagonists

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CYTOKINE; FLUTICASONE PROPIONATE; LONG ACTING DRUG; SALMETEROL;

ASTHMA; BRONCHUS BIOPSY; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0038676263     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1589     Document Type: Article

References (16)

1. National Heart, Lung and Blood Institute, National Institutes for Health. Global strategy for asthma management and prevention, revised 2002. Bethesda, Md: National Heart, Lung and Blood Institute, National Institutes for Health; 2002.
2. McIvor R, Pizzichini E, Turner M, Hussack P, Hargreave F, Scars M. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30.
3. Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 2003;112:72-8.
4. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:253-6.
5. Gershman N, Wong H, Liu J, Fahy J. Low and high dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000;15:11-8.
6. Visser M, Postma D, Arends L, De Vries T, Duiverman E. One year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Am J Respir Crit Care Med 2001;164:2073-7.
7. O'Sullivan S, Cormican L, Murphy M, Poulter LW, Burke CM. Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma. Chest 2002;122:1966-72.
8. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73.
9. Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999;14:627-32.
10. Condemi J, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999;82:383-9.
11. Greening A, Ind P, Northfield M, Shaw G. Added salmeterol versus high dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
12. Kips J, O'Connor B, Inman M, Svensson K, Pauwels R, O'Byrne P. A long term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000;161:996-1001.
13. 2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999:160:1493-9.
14. Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback B, Della-Cioppa G, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999;159:79-86.
15. Arvidsson P, Larsson S, Löfdahl C-G, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991;4:1168-73.
16. Barnes P. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.